Jobs / United States / Glaxosmithkline LLC
Director, Specialty & Emerging Pharmacy Channels
Glaxosmithkline LLC · 🇺🇸 Field Worker - USA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles4 certified filings for “Associate Director – Genomic Technologies” (Molecular and Cellular Biologists) in PA: $134k–$138k, median $136k. Most were filed at wage level IV (50%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Last confirmed live 1 day agoWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
Director, Specialty & Emerging Pharmacy Channel Accounts Background: Specialty pharmacy (SP) is the primary dispensing channel for oncology, rare disease, and REMS ( Risk Evaluation and Mitigation Strategies ) governed products . T he commercial complexity of managing SP partners goes well beyond distribution. SP clinical pharmacists are active participants in patient care; SP data reporting is a core source of pull-through intelligence; and SP REMS compliance is a regulatory obligation with commercial consequences. At the same time, the dispensing landscape is being reshaped by emerging digital pharmacy entrants, each representing a distinct disruptive model that creates both commercial risk and patient access opportunity for the portfolio. These SP and emerging pharmacy questions are no longer separable strategic challenges. Role Description: The Director, Specialty & Emerging Pharmacy Channels is the Market Access account leader responsible for commercial performance, pull-through execution, and strategic engagement across two converging channel segments: the traditional specialty pharmacy network serving oncology and specialty products, and the emerging digital and disruptive pharmacy entrants reshaping patient access to specialty and chronic medications. This role reports to the FVP, Enterprise Distribution & Channel. Th e role is responsible for : 1) Managing SP partners against performance scorecards — driving pull-through in oncology and specialty therapeutic areas, governing REMS-compliant dispensing relationships, and ensuring SP integration with brand hub and patient access infrastructure. 2) Building manufacturer engagement frameworks for emerging digital pharmacy entrants where no established playbook exists — defining commercial posture, monitoring G ro s s T o N et ( GTN ) and pricing implications, and identifying legitimate patient access opportunities. 3) Owning SP and emerging pharmacy channel pull-through analytics, performance reporting, and field intelligence. 4) Serving as the field interface with Brand Hub, Patient Services, Payer Access, and Medical Affairs on SP clinical engagement. Specific responsibilities include: • Own commercial field relationships with SP partners — driving pull-through, patient access performance, and contractual compliance across the SP network. • Execute SP performance scorecards — tracking time-to-fill, dispense rates, REMS compliance, hub handoff quality, patient persistence, and data reporting timeliness — deploying corrective actions before gaps affect patient access. • Lead SP clinical pharmacist engagement in oncology and specialty therapeutic areas — equipping SP clinical staff with product knowledge, support tools, and patient access resources to support dispensing excellence. • For REMS-governed and LDD products, serve as the field account lead for SP REMS compliance monitoring, certified pharmacy network management, and patient enrollment support. • Own the enterprise commercial relationship and engagement strategy for emerging digital pharmacy entrants — developing manufacturer engagement frameworks where established pharma playbooks do not yet exist. • Monitor portfolio product inclusion on cash-pay and transparent-pricing digital pharmacy platforms — assessing pricing transparency implications for WAC strategy and GTN accruals, escalating pricing signal anomalies to ETAC Strategy and Finance. • Define and execute the channel conflict governance protocol for emerging digital pharmacy — identifying which portfolio products are appropriate for digital pharmacy dispensing vs. require SP-channel exclusivity. • Monitor emerging digital pharmacy entrants — including em